95 results
Page 2 of 5
8-K
EX-5.1
clksbsd6
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
nwmmz 8eb1scxy6mjqj
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
424B5
zv0js4
24 Mar 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-5.1
xzp0ocm ig6x9l
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-1.1
gljyklwm13q2liccngs
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
p42x1h2
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
o8tv gwhfv7c
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.1
6x6vs89i9soiw urxk
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-99.1
62z6bgmyv6q 5q
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.3
joke8j0 ichx
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-99.1
n6la5n3gwqo
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
8-K
EX-1.1
ze3 g8gd5z4
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm